EMBOLIZATION OF RENAL ANGIOMYOLIPOMA: CASE SERIES
Abstract
Renal angiomyolipomas (AML) are benign lesions usually left alone. However, lesions larger than 4 cm carry the risk of spontaneous haemorrhage and need treatment. Angiography and embolisation are the current standard of care particularly in patients with high operative risks. Angio-embolisation is a safe, minimally invasive procedure preserving maximum renal parenchyma, with the added advantage of preventing peri-procedural morbidity. Two cases of AML are presented in this case series.
Key words: Angiomyolipoma, embolisation, renal
References
Choe J, Shin JH, Yoon HK, et al. Safety and ef cacy of transarterial nephrectomy as an alternaterive to surgical nephrectomy. Korean J Radiol 2014;15:472-80.
Huang Q, Zhai RY. Embolization of symptomatic renal angiomyolipoma with a mixture of lipoidal and PVA, a mid-term result. Chin J Cancer Res 2014;26:399-403.
Davis NF, Kelly R, Lee MJ, et al. Selective arterial embolization of bilateral angiomyolipomata in a symptomatic pregnant female. BMJ Case Rep 2013;2013:bcr2013009256.
Patatas K, Robinson GJ, Ettles DF, et al. Patterns of renal angiomyolipoma regression post embolisation on medium to long term follow up. Br J Radiol 2013;86:20120633.
Villalta JD, Sorensen MD, Durack JC, et al. Selective arterial embolization of angiomyolipomas: A comparison of smaller and larger embolic agents. J Urol 2011;186: 921-7.
Mues AC, Palacios JM, Haramis G, et al. Contemporary experience in the management of angiomyolipoma. J Endourol 2010;24:1883-6.
Sivalingam S, Nakada SY. Contemporary minimally invasive treatment options for renal angiomyolipomas. Curr Urol Rep 2013;14:147-53.
Faddegon S, So A. Treatment of angioyolipoma at a tertiary care centre: The decision between surgery and angioembolization. Can Urol Assoc J 2011;5:E138-41.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.